C6498
Anti-CYP26A1 (481-495) antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Synonym(s):
Anti-CP26, Anti-CYP26, Anti-Cytochrome P450, family 26, subfamily A, polypeptide 1 isoform 1, Anti-P450RAI, Anti-P450RAI1
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
5
biological source
rabbit
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~56 kDa
species reactivity
human
technique(s)
western blot: 1:500-1:1,000
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... CYP26A1(1592)
General description
Cytochrome P450 26A1 is a protein encoded by the CYP26A1 gene in humans. It is mapped on human chromosome 10q23-q24. CYP26A1 gene encodes cytochrome P450 enzyme, specifically involved in metabolic inactivation of retinoic acid (RA).
Immunogen
synthetic peptide corresponding to amino acids 481-495 of human CYP26A1
Application
Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if. Anti-CYP26A1 (481-495) antibody produced in rabbit is suitable for western blotting at a dilution of 1:500-1:1,000.
Biochem/physiol Actions
CYP26A1 promotes cell survival properties and contributes to the carcinogenic process. Enhanced CYP26A1 expression causes a functional Vitamin A deficiency (VAD) state in skin that leads to neoplastic transformation of keratinocytes in an early phase during skin carcinogenesis. It has high ligand selectivity but accepts structurally related nuclear receptor agonists as inhibitors. CYP26A1 is the P450 isoform and can be targeted when designing retinoic acid (RA) metabolism blocking agents.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jayne E Thatcher et al.
Biochemical pharmacology, 80(6), 903-912 (2010-06-02)
All-trans retinoic acid (RA) is a critical signaling molecule and its concentration is tightly regulated. Several P450 enzymes including CYP26A1, CYP2C8, and CYP3A4 have been proposed to be responsible for RA clearance in the liver but their quantitative importance has
Makoto Osanai et al.
Medical molecular morphology, 44(4), 200-206 (2011-12-20)
Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis. CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, has been shown to result in
Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Jayne E Thatcher et al.
Molecular pharmacology, 80(2), 228-239 (2011-04-28)
All-trans-retinoic acid (atRA) is the active metabolite of vitamin A. atRA is also used as a drug, and synthetic atRA analogs and inhibitors of retinoic acid (RA) metabolism have been developed. The hepatic clearance of atRA is mediated primarily by
P450RAI (CYP26A1) maps to human chromosome 10q23-q24 and mouse chromosome 19C2-3.
J A White et al.
Genomics, 48(2), 270-272 (1998-04-02)
John-Poul Ng-Blichfeldt et al.
Thorax, 72(6), 510-521 (2017-01-15)
Molecular pathways that regulate alveolar development and adult repair represent potential therapeutic targets for emphysema. Signalling via retinoic acid (RA), derived from vitamin A, is required for mammalian alveologenesis, and exogenous RA can induce alveolar regeneration in rodents. Little is
Articles
Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.
一期生物转化反应在药物上引入或暴露官能团，目的是增加化合物的极性。尽管一期药物代谢发生在大多数组织中，但代谢的主要和首过部位发生在肝循环期间。
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service